Clinical trials: Epirubicin
Breast Neoplasms
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
The purpose of this study is to compare the safety and efficacy of epirubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide in lymph node negative, estrogen receptor (ER) positive, human epithelial growth factor…
- Trial name
- ELEGANT (NCT02549677)
- Testing
- Epirubicin, Docetaxel, cyclophosphamide
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Ruijin Hospital
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
This is a multicentre phase III open-labelled, randomised controlled trial. Eligible patients will be randomised in a 1:1 fashion between neoadjuvant and adjuvant chemotherapy (Investigator's choice modified MAGIC (ECF/ECX or…
- Conditions
- Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours, Junctional Tumours
- Trial name
- NCT01726452
- Testing
- Epirubicin, Cisplatin / Oxaliplatin, 5 Flourouracil/ Capecitabine
- Where
- 29 sites in Denmark, France and 3 more
- Volunteers
- 377 people
- Sponsor
- Cancer Trials Ireland
Non-muscle-invasive Bladder Cancer
Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
This project will conduct a large-sample, multi-center prospective clinical trial to further establish the safety and efficacy of BL-5ALA-PDT in preventing Non-Muscle Invasive Bladder Cancer (NMIBC) recurrence when compared to…
- Trial name
- BL-PDT-RCT (NCT05547516)
- Testing
- Standard infusion chemotherapy, BL - 5 ala PDT
- Where
- China
- Volunteers
- 140 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Triple-Negative Breast Cancer
DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Both DCb (docetaxel/carboplatin) and EC followed by D (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been recommended by NCCN guideline.
- Trial name
- NCT03154749
- Testing
- DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087178
- Testing
- cyclophosphamide, adriamycin, epirubicin
- Where
- 606 sites in United States, Canada and 1 more
- Volunteers
- 2,722 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer, TNBC - Triple-Negative Breast Cancer
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
To investigate the efficacy and safety of terbinumab combined with chemotherapy (epirubicin + cyclophosphamide → nab-paclitaxel + carboplatin) in neoadjuvant therapy of triple-negative breast cancer after HIFU.
- Trial name
- HIFU (NCT05491694)
- Testing
- Toripalimab, Epirubicin, High Intensity Focused Ultrasoun
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Stage II-III Breast Cancer
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety of the combination of traditional herbal medicine for cancer immunotherapy and neoadjuvant therapy versus neoadjuvant therapy in…
- Trial name
- NCT05483439
- Testing
- cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin), anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab), traditional herbal medicine
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Shengjing Hospital
Hepatocellular Carcinoma
TACE With Dicycloplatin(TP21) in Unresectable HCC
To evaluate the effectiveness and safety of TP21 injection for TACE in treatment of hepatocellular carcinoma: 1. Primary efficacy endpoint: progression-free survival (PFS), which will be assessed by the Independent Review…
- Trial name
- NCT05472896
- Testing
- cTACE, Dicycloplatin (TP21), Epirubicin
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Gao-jun Teng
Breast Cancer
A Study for the Neoadjuvant Treatment of Breast Cancer
Due to the unique advantages of albumin-bound paclitaxel, several studies in China and abroad have tried to use albumin-bound paclitaxel for neoadjuvant treatment of breast cancer up to now.
- Trial name
- NCT05420454
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- China
- Volunteers
- 1,576 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
A Study for the Adjuvant Treatment of Breast Cancer
Studies on postoperative adjuvant albumin paclitaxel in domestic breast cancer patients are less reported, especially in large samples, and more studies focus more on the safety and tolerability of albumin paclitaxel use.
- Trial name
- NCT05420467
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- China
- Volunteers
- 2,413 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Stage III Breast Cancer AJCC V7
Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer
Molecular markers predicting response to dose dense chemotherapy with epirubicin and docetaxel in sequence for locally advanced breast cancer Protocol summary. Principal Investigator Hans P. Eikesdal, Professor, Dept.
- Trial name
- DDP (NCT00496795)
- Testing
- epirubicin/docetaxel sequential
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- University of Bergen
Breast Cancer
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant…
- Trial name
- NCT01966471
- Testing
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab
- Where
- 295 sites in United States, Australia and 34 more
- Volunteers
- 1,846 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
Neoadjuvant therapy for HR+/HER2- breast cancer is dominated by anthracycline combined with paclitaxel chemotherapy. Aggressive neoadjuvant chemotherapy can only achieve pCR in about 10% of PATIENTS with HR-positive breast…
- Trial name
- NCT05400993
- Testing
- Chidamide
- Where
- 7 sites in China
- Volunteers
- 59 people
- Sponsor
- Shengjing Hospital
Breast Cancer
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
This multi-center, open-label, phase II randomized controlled trial is to evaluate the efficacy of docetaxel(T) combined with metronomic cyclophosphamide/capecitabine (mCX) followed by fluorouracil /epirubicin/cyclophosphamide…
- Trial name
- NCT02897050
- Testing
- Docetaxel, Capecitabine, Cyclophosphamide (tablet)
- Where
- 4 sites in China
- Volunteers
- 170 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
pCR Rate, BCT Rate
NeoMET Study in Neoadjuvant Treatment of Breast Cancer
To evaluate docetaxel, epirubicin and cyclophosphomide (TEC) with TEC plus metformin in neoadjuvant treatment of breast cancer patients.
- Conditions
- pCR Rate, BCT Rate, Safety
- Trial name
- NeoMET (NCT01929811)
- Testing
- Metformin, Docetaxel, Epirubicin
- Where
- 2 sites in China
- Volunteers
- 92 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
HER2-negative Early Breast Cancer
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with triple negative subtype who achieved pCR after neoadjuvant treatment would have longer survival.
- Trial name
- NCT04836156
- Testing
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer, neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University People's Hospital
Breast Cancer
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.
- Trial name
- NCT05287308
- Testing
- doxorubicin, epirubicin, pirarubicin
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Chinese Academy of Medical Sciences
Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
This phase II trial studies how well sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery work in treating patients with high-risk stage IIB-IV soft tissue sarcoma.
- Conditions
- Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
- Trial name
- NCT02050919
- Testing
- Epirubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Neoadjuvant Operable Breast Cancer
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
The investigators propose in the present study an innovative approach, combining the most recent therapeutic opportunities in high risk ER+ breast cancer with the most recent and innovative diagnostic approaches such as the PAM50…
- Trial name
- NeoPAL (NCT02400567)
- Testing
- Fluorouracile, Epirubicin, Cyclophosphamide
- Where
- 2 sites in France
- Volunteers
- 125 people
- Sponsor
- UNICANCER
Breast Neoplasms
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
This is an open, multicenter, randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane (+/- goserelin) versus chemotherapy in the neoadjuvant treatment of stage II-III HR…
- Trial name
- NCT05253066
- Testing
- Chidamide combined with exemestane (+/- goserelin), Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
- Volunteers
- 130 people
- Sponsor
- Shengjing Hospital